Prognostic role of antibody reactivity to XXXX .

@entity1 @entity92 @entity4182 @entity320
Antibody reactivity against cultured allogeneic @entity320 Y-Mel 81:180 was studied in 43 @entity1 who participated in an adjuvant trial for stage I and II @entity320 . Serum samples were obtained at trial entry within 2 mo of definitive surgery. At the time of serum acquisition, all @entity1 were free of disease by physical examination and routine radiologic and laboratory parameters. Serum antibody reactivity was tested for by protein A hemadsorption before and after acid dissociation and ultrafiltration of serum. We have previously shown that this technique for immune complex dissociation augments autologous antibody reactivity. Results of serum antibody reactivity were scored by an investigator blinded to the @entity1 's clinical status. Of the 43 @entity1 studied, 15 relapsed and 28 remained disease-free. At study entry, there were 25 stage I @entity1 and 18 stage II @entity1 . @entity92 was 3.25 +/- 2.5 mm in relapse @entity1 and 1.67 +/- 1.1 mm in disease-free @entity1 . The presence and titer of antibody directed against @entity320 in either native serum or serum dissociated from immune complexes was found to be associated with eventual relapse (P = 0.0001). When results were subgrouped by stage of disease, @entity92 , and @entity4182 , antibody reactivity was still correlated with eventual relapse. The incidence and titer of antibody reactivity against @entity320 appears to be a new prognostic factor in predicting eventual disease recurrence.
